Literature DB >> 17982578

An emerging role for the delta opioid receptor in the regulation of mu opioid receptor function.

Raphael Rozenfeld1, Noura S Abul-Husn, Ivone Gomez, Lakshmi A Devi.   

Abstract

Morphine and related opiates are commonly used in the clinical management of various types of pain. However, the antinociceptive properties of morphine are often overshadowed by the development of tolerance and dependence following its chronic use. The mechanisms underlying opiate tolerance are not fully understood, but appear to involve numerous and complex physiological adaptations. Recently, a role for the heterodimerization of mu and delta opioid receptors in the development of morphine tolerance has been proposed. This novel mechanism could help us to understand several observations, such as the critical role of delta opioid receptor regulation, the impact of delta opioid receptor binding site occupancy, and the participation of beta-arrestin2, in the development of morphine tolerance.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17982578      PMCID: PMC5901224          DOI: 10.1100/tsw.2007.219

Source DB:  PubMed          Journal:  ScientificWorldJournal        ISSN: 1537-744X


  22 in total

Review 1.  On the expanding terminology in the GPCR field: the meaning of receptor mosaics and receptor heteromers.

Authors:  Luigi F Agnati; Diego Guidolin; Jean Pierre Vilardaga; Francisco Ciruela; Kjell Fuxe
Journal:  J Recept Signal Transduct Res       Date:  2010-10       Impact factor: 2.092

2.  Novel screening assay for the selective detection of G-protein-coupled receptor heteromer signaling.

Authors:  Richard M van Rijn; Jessica H Harvey; Daniela I Brissett; Julia N DeFriel; Jennifer L Whistler
Journal:  J Pharmacol Exp Ther       Date:  2012-10-24       Impact factor: 4.030

3.  YFa and analogs: investigation of opioid receptors in smooth muscle contraction.

Authors:  Krishan Kumar; Ritika Goyal; Annu Mudgal; Anita Mohan; Santosh Pasha
Journal:  World J Gastroenterol       Date:  2011-10-28       Impact factor: 5.742

4.  Opiate antagonist prevents μ- and δ-opiate receptor dimerization to facilitate ability of agonist to control ethanol-altered natural killer cell functions and mammary tumor growth.

Authors:  Dipak K Sarkar; Amitabha Sengupta; Changqing Zhang; Nadka Boyadjieva; Sengottuvelan Murugan
Journal:  J Biol Chem       Date:  2012-03-27       Impact factor: 5.157

5.  In vivo characterization of MMP-2200, a mixed δ/μ opioid agonist, in mice.

Authors:  John J Lowery; Tyler J Raymond; Denise Giuvelis; Jean M Bidlack; Robin Polt; Edward J Bilsky
Journal:  J Pharmacol Exp Ther       Date:  2010-11-30       Impact factor: 4.030

6.  Disruption of δ-opioid receptor phosphorylation at threonine 161 attenuates morphine tolerance in rats with CFA-induced inflammatory hypersensitivity.

Authors:  Hai-Jing Chen; Wei-Yan Xie; Fang Hu; Ying Zhang; Jun Wang; Yun Wang
Journal:  Neurosci Bull       Date:  2012-04       Impact factor: 5.203

7.  Pentapeptides displaying mu opioid receptor agonist and delta opioid receptor partial agonist/antagonist properties.

Authors:  Lauren C Purington; Irina D Pogozheva; John R Traynor; Henry I Mosberg
Journal:  J Med Chem       Date:  2009-12-10       Impact factor: 7.446

8.  Analgesia and central side-effects: two separate dimensions of morphine response.

Authors:  Joanne M Droney; Sophy K Gretton; Hiroe Sato; Joy R Ross; Ruth Branford; Kenneth I Welsh; William Cookson; Julia Riley
Journal:  Br J Clin Pharmacol       Date:  2013-05       Impact factor: 4.335

9.  Augmentation of morphine-induced sensitization but reduction in morphine tolerance and reward in delta-opioid receptor knockout mice.

Authors:  V I Chefer; T S Shippenberg
Journal:  Neuropsychopharmacology       Date:  2008-08-13       Impact factor: 7.853

10.  Intrathecal rapamycin attenuates morphine-induced analgesic tolerance and hyperalgesia in rats with neuropathic pain.

Authors:  Ji-Tian Xu; Linlin Sun; Brianna Marie Lutz; Alex Bekker; Yuan-Xiang Tao
Journal:  Transl Perioper Pain Med       Date:  2015
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.